Compound · clinical trials

Folfox clinical trials

Also listed in trial records as Folfiri, Capox, Fluorouracil (5-FU), Oxaliplatin/capecitabine, 5-fluorouracil, Calcium folinate and Irinotecan, Capecitaine, Leucovorin/Fluorouracil/Oxaliplatin, Doublet

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 108 trials in our China, USA, France, Spain, Italy, South Korea, Australia, Germany, UK, Canada, Japan, Belgium, Poland, Taiwan, Netherlands, Brazil, Denmark, Mexico, Austria, Czechia, Portugal, Turkey, Sweden, Norway, India, Switzerland, Ireland, Singapore, Israel and Egypt registers that name Folfox as an intervention. Synced 10 Nov 2026

108Current trials

67Recruiting now

80Lead sponsors

30Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 10 Nov 2026 · Editorial standards

At a glance

Folfox is named as an intervention in 108 current clinical trials in our China, USA, France, Spain, Italy, South Korea, Australia, Germany, UK, Canada, Japan, Belgium, Poland, Taiwan, Netherlands, Brazil, Denmark, Mexico, Austria, Czechia, Portugal, Turkey, Sweden, Norway, India, Switzerland, Ireland, Singapore, Israel and Egypt registers. 67 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Fudan University (8). The most-studied condition is Colorectal Cancer.

Patient leaflets for Folfox

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting6762%
Not yet open2321%
Active, closed1716%
By invitation11%

Trials by phase

Phase 24844%
Phase 32725%
Phase 11514%
Phase 1/21211%
Phase 2/344%
Not applicable11%
Observational11%

Clinical trials of Folfox

108 trials

Study	Phase	Status	Lead sponsor	Registers
Induction Chemotherapy for Locally Recurrent Rectal Cancer NCT04389086 · ClinicalTrials.gov ↗ · Recurrent Rectal Cancer	Phase 3	Recruiting	Catharina Ziekenhuis Eindhoven	Netherlands, Belgium, Sweden, Norway, Portugal
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) NCT05008809 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 3	Recruiting	Dominik Paul Modest	Germany
Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12) NCT05534087 · ClinicalTrials.gov ↗ · Colon Cancer	Phase 3	Recruiting	Seoul National University Hospital	South Korea
TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer NCT05646511 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 3	Recruiting	National Cancer Center Hospital East	Japan
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer NCT05855200 · Colonic Neoplasms, Neoplasms, Colon	Phase 3	Recruiting	GlaxoSmithKline	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation NCT06252649 · Metastatic Colorectal Cancer	Phase 3	Recruiting	Amgen	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or More NCT06293625 · ClinicalTrials.gov ↗ · Colon Cancer	Phase 3	Recruiting	Centre Hospitalier Universitaire Dijon	France
Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer NCT06783491 · ClinicalTrials.gov ↗ · Locally Advanced Colorectal Cancer	Phase 3	Recruiting	Maimónides Biomedical Research Institute of Córdoba	Spain
Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study NCT07132463 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 3	Recruiting	Fudan University	China
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer NCT07284849 · CRC (Colorectal Cancer)	Phase 3	Recruiting	Incyte Corporation	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Austria, Norway, Canada, Brazil, Japan, South Korea, Australia, Israel
NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer NCT07309289 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (CRC)	Phase 3	Recruiting	Shanghai Zhongshan Hospital	China
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. NCT07315750 · ClinicalTrials.gov ↗ · Gastric Carcinoma	Phase 3	Recruiting	RemeGen Co., Ltd	China
Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer NCT07389265 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (mCRC)	Phase 3	Recruiting	University of Campania Luigi Vanvitelli	Spain, Italy
Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer NCT07472868 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Carcinoma	Phase 3	Recruiting	J. W. A. Burger	Netherlands
Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer NCT07528209 · ClinicalTrials.gov ↗ · Rectal Cancer, pMMR (Microsatellite Stable Rectal Cancer)	Phase 3	Recruiting	Sun Yat-sen University	China
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma NCT07700979 · Gastric / Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Akeso	USA, China, Germany, Poland
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1) NCT07702032 · Left-sided Colorectal Cancer	Phase 3	Recruiting	Genmab	USA, Australia
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) NCT07221149 · Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma	Phase 2/3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China, Germany, France, Spain, Italy, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer NCT07221357 · Untreated, Unresectable, or Metastatic Colorectal Cancer	Phase 2/3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma NCT05702229 · Gastric Cancer	Phase 2	Recruiting	AstraZeneca	UK, USA, China, Spain, Japan, South Korea, Taiwan
Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer NCT06154538 · ClinicalTrials.gov ↗ · Locally Advanced Colorectal Carcinoma	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer NCT06218810 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma, RAS Mutation	Phase 2	Recruiting	Fudan University	China
First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer NCT06253611 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	GERCOR - Multidisciplinary Oncology Cooperative Group	France
Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme NCT06475352 · ClinicalTrials.gov ↗ · Digestive Cancer, Colorectal Cancer	Phase 2	Recruiting	UNICANCER	France
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients NCT06529718 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Recruiting	UNICANCER	France
A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM NCT06590259 · ClinicalTrials.gov ↗ · Colorectal Cancer Liver Metastasis	Phase 2	Recruiting	Shanghai 6th People's Hospital	China
Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer NCT06603376 · ClinicalTrials.gov ↗ · Colorectal Carcinoma	Phase 2	Recruiting	Shanghai Changzheng Hospital	China
A Phase 2 Clinical Study of ABSK061 and ABSK043 NCT06632262 · ClinicalTrials.gov ↗ · HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer	Phase 2	Recruiting	Abbisko Therapeutics Co, Ltd	China
Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy NCT06826092 · ClinicalTrials.gov ↗ · Progression-Free Survival	Phase 2	Recruiting	Kaohsiung Medical University Chung-Ho Memorial Hospital	Taiwan
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma NCT06846346 · ClinicalTrials.gov ↗ · Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma	Phase 2	Recruiting	UNICANCER	France
Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01) NCT06860477 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocellular Carcinoma	Phase 2	Recruiting	Fudan University	China
Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1) NCT06907342 · ClinicalTrials.gov ↗ · Tumor, Colorectal, Organoids, Tumoroid	Phase 2	Recruiting	St. Olavs Hospital	Norway
Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color） NCT06949111 · Colon Cancer	Phase 2	Recruiting	Hebei Medical University Fourth Hospital	China
Organ Preservation in Rectal AdenoCa Using Hypofractionated Pelvic RT(Hypo-OPRA) NCT06991465 · ClinicalTrials.gov ↗ · Colorectal Carcinoma	Phase 2	Recruiting	Neil Kopek	Canada
Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial NCT07106034 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer	Phase 2	Recruiting	Shanghai Pudong Hospital	China
Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer NCT07154316 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Recruiting	Fudan University	China
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab NCT07192185 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2	Recruiting	Sun Yat-sen University	China
PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer NCT07294664 · ClinicalTrials.gov ↗ · Advanced Gastric Cancer, SHR1701	Phase 2	Recruiting	The First Affiliated Hospital of Zhengzhou University	China
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer NCT07446322 · Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer	Phase 2	Recruiting	Oncolytics Biotech	USA
A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer NCT07562490 · ClinicalTrials.gov ↗ · ctDNA, Chemotherapy, Colorectal Cancer	Phase 2	Recruiting	Fudan University	China
Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer NCT07562711 · ClinicalTrials.gov ↗ · ctDNA, Chemotherapy, Colorectal Cancer	Phase 2	Recruiting	Fudan University	China
Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC NCT07646639 · ClinicalTrials.gov ↗ · Rectal Cancer, Radiotherapy	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
TAIC FOLFOX for Locally Advanced G/GEJA NCT07655024 · ClinicalTrials.gov ↗ · Gastric Cancer (Diagnosis), Gastroesophageal Junction Adenocarcinoma	Phase 2	Recruiting	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	China
Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM NCT07728019 · ClinicalTrials.gov ↗ · CRC (Colorectal Cancer)	Phase 2	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer NCT07888309 · ClinicalTrials.gov ↗ · Rectal Neoplasms, Rectal Cancer, Adenocarcinoma	Phase 2	Recruiting	Ruijin Hospital	China
NeoCSR-Omics Trial: CAPOX + Serplulimab Before vs. After Short-course RT in LARC NCT07898865 · ClinicalTrials.gov ↗ · Rectal Cancer Patients, Locally Advanced Rectal Cancer (LARC)	Phase 2	Recruiting	Chongqing University Cancer Hospital	China
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) NCT05482893 · Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)	Phase 1/2	Recruiting	Phanes Therapeutics	USA
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis	Phase 1/2	Recruiting	Institut de Recherches Internationales Servier	China, France, Spain, Italy, Denmark, Japan, Australia
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors NCT06445062 · Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma	Phase 1/2	Recruiting	Revolution Medicines, Inc	USA
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors NCT06598007 · Solid Tumor, Adult, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma	Phase 1/2	Recruiting	Crossignal Therapeutics, Inc	USA
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer NCT07204574 · ClinicalTrials.gov ↗ · CRC	Phase 1/2	Recruiting	Chang Gung Memorial Hospital	Taiwan
A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma NCT07327229 · ClinicalTrials.gov ↗ · Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 1/2	Recruiting	Antengene Biologics Limited	China
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors NCT07335497 · Locally Advanced / Metastatic Solid Tumors	Phase 1/2	Recruiting	Crescent Biopharma, Inc	Ireland, UK, USA, France, Spain, Italy, South Korea, Australia
HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer NCT07790510 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (CRC)	Phase 1/2	Recruiting	Haisco Pharmaceutical Group Co., Ltd	China
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells NCT03692429 · Unresectable Metastatic Colorectal Cancer	Phase 1	Recruiting	Celyad Oncology SA	USA, Belgium
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) NCT04929223 · Metastatic Colorectal Cancer	Phase 1	Recruiting	Hoffmann-La Roche	UK, USA, Germany, Spain, Italy, Denmark, Poland, Canada, South Korea, Taiwan, Australia
Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer NCT04991948 · Unresectable Metastatic Colorectal Cancer	Phase 1	Recruiting	Celyad Oncology SA	USA, Belgium
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors NCT05836324 · Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors	Phase 1	Recruiting	Incyte Corporation	UK, USA, China, France, Spain, Italy, Denmark, Switzerland, Japan
Preoperative Radiotherapy And ASTX660 in Rectum Cancer NCT05912075 · ClinicalTrials.gov ↗ · Locally-advanced Rectal Cancer	Phase 1	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	France
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation NCT06179160 · Solid Tumors	Phase 1	Recruiting	Incyte Corporation	USA, France, Spain, Italy, Belgium, Canada, Japan, Australia
SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor NCT06350006 · ClinicalTrials.gov ↗ · CLDN18.2-positive Advanced Solid Tumor	Phase 1	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd	China
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors NCT06621563 · ClinicalTrials.gov ↗ · Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer	Phase 1	Recruiting	Hansoh BioMedical R&D Company	China
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors NCT06625775 · Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer	Phase 1	Recruiting	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	USA, France, Spain, Brazil, South Korea, Australia
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers NCT06663319 · Colorectal Neoplasms, Gastrointestinal Neoplasms	Phase 1	Recruiting	Janssen Research & Development, LLC	USA, Spain, South Korea
A Study of PHST001 in Advanced Solid Tumors NCT06840886 · Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer	Phase 1	Recruiting	Pheast Therapeutics	USA
EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer NCT07649655 · ClinicalTrials.gov ↗ · Unresectable/Metastatic Colorectal Cancer	Phase 1	Recruiting	Shanghai EpimAb Biotherapeutics Co., Ltd	China
The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer. NCT06068023 · ClinicalTrials.gov ↗ · Ampullary Adenocarcinoma	Observational	Recruiting	Fondazione Poliambulanza Istituto Ospedaliero	Italy
Pre-Operative Treatment in REseCTable COlon CanceR NCT06899477 · ClinicalTrials.gov ↗ · Colo-rectal Cancer, Colon Cancer, Colon Carcinoma	Phase 3	Not yet open	Dominik Paul Modest	Germany
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients NCT07004413 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 3	Not yet open	Charite University, Berlin, Germany	Germany
Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer NCT07068516 · ClinicalTrials.gov ↗ · Gastric Cancer Stage	Phase 3	Not yet open	Xiangdong Cheng	China
Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer NCT07074353 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 3	Not yet open	Zhejiang Cancer Hospital	China
A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma NCT07595913 · ClinicalTrials.gov ↗ · Neuroendocrine Carcinoma	Phase 3	Not yet open	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	China
Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial NCT07686796 · ClinicalTrials.gov ↗ · Local Advanced Rectal Cancer, PD-1 Inhibitor, PCSK9 Inhibitor	Phase 3	Not yet open	Guangdong Provincial People's Hospital	China
FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC NCT07729605 · Colorectal Cancer Metastatic, Microsatellite Stable (MSS) Colorectal Cancer (CRC)	Phase 3	Not yet open	Sun Yat-sen University	China
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma NCT07763171 · ClinicalTrials.gov ↗ · Gastroesophageal Adenocarcinoma	Phase 3	Not yet open	Gruppo Oncologico del Nord-Ovest	Germany, Spain, Italy
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment NCT06662877 · ClinicalTrials.gov ↗ · Biliary Tract Cancer, Second Line Treatment, Chemotherapy	Phase 2/3	Not yet open	Sun Yat-sen University	China
Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer NCT05969847 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 2	Not yet open	池畔	China
An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment. NCT06855849 · ClinicalTrials.gov ↗ · RAS/BRAF Wild-type Advanced Colorectal Cancer Patients	Phase 2	Not yet open	Yonsei University	South Korea
Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06) NCT06919848 · ClinicalTrials.gov ↗ · Biliary Tract Cancer (BTC)	Phase 2	Not yet open	Fudan University	China
Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment：an Open-label, Randomized, Controlled Phase II Clinical Study NCT06946849 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc)	Phase 2	Not yet open	Shanghai Zhongshan Hospital	China
Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC NCT07070713 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy	Phase 2	Not yet open	Fujian Cancer Hospital	China
SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer NCT07297030 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 2	Not yet open	Sun Yat-sen University	China
Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01) NCT07337447 · Carcinoma, Neuroendocrine	Phase 2	Not yet open	Hospices Civils de Lyon	France
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma NCT07353827 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc), Hepatic Arterial Infusion Chemotherapy	Phase 2	Not yet open	Sun Yat-sen University	China
KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer NCT07622017 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 2	Not yet open	Gustave Roussy, Cancer Campus, Grand Paris	France
Phase II Study of Trastuzumab Rezetecan Combined With Retlirafusp Alfa With or Without CAPOX as Perioperative Therapy for Resectable Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma NCT07802288 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer NCT06871527 · ClinicalTrials.gov ↗ · Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Fruquintinib	Phase 1/2	Not yet open	Sixth Affiliated Hospital, Sun Yat-sen University	China
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation NCT07391566 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (mCRC)	Phase 1/2	Not yet open	Luye Pharma Group Ltd	China
LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer NCT07453875 · ClinicalTrials.gov ↗ · Peritoneal Metastasis of Gastric and Colorectal Cancer, LDRT	Phase 1	Not yet open	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	China
To Explore a Single-arm Phase II Study on Intestinal Microbiota Transplantation Combined With Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Rectal Cancer Under MSS/pMMR NCT07738042 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer (LARC)	Not applicable	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer NCT06959589 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic, KRAS G12C Mutation	Phase 2	By invitation	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) NCT04793958 · Advanced Colorectal Cancer, Metastatic Colorectal Cancer	Phase 3	Active, closed	Mirati Therapeutics Inc	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Austria, Czechia, Portugal, Canada, Brazil, Mexico, South Korea, Taiwan, Singapore, Australia, Egypt
Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test NCT07340567 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 3	Active, closed	UNICANCER	France, Sweden
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer NCT05462613 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2/3	Active, closed	Centre Hospitalier Universitaire de Besancon	France
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC NCT03806309 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer	Phase 2	Active, closed	GERCOR - Multidisciplinary Oncology Cooperative Group	France
Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status. NCT04348045 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Adenocarcinoma	Phase 2	Active, closed	GERCOR - Multidisciplinary Oncology Cooperative Group	France
Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease NCT04595266 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer	Phase 2	Active, closed	Grupo Espanol Multidisciplinario del Cancer Digestivo	Spain
CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen NCT05312398 · ClinicalTrials.gov ↗ · Metastatic Colorectal Adenocarcinoma	Phase 2	Active, closed	University of Campania Luigi Vanvitelli	Italy
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer NCT05476796 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 2	Active, closed	UNICANCER	France
A Study of PM8002 in Combination With Chemotherapy in Patients With NEN NCT05879055 · ClinicalTrials.gov ↗ · Neuroendocrine Neoplasm	Phase 2	Active, closed	Biotheus Inc	China
Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer NCT05969899 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Active, closed	Fudan University	China
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation NCT06106308 · Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation	Phase 2	Active, closed	Cardiff Oncology	USA
Neoadjuvant Short-Course Radiotherapy Followed by CAPOX Plus PD-1 Antibody and IL-2 in Locally Advanced Rectal Cancer (PRIDE01) NCT06577194 · ClinicalTrials.gov ↗ · Rectal Cancer, Advanced Solid Tumor	Phase 2	Active, closed	The First Affiliated Hospital with Nanjing Medical University	China
Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II-III NCT07821333 · ClinicalTrials.gov ↗ · Colorectal Neoplasms Malignant, Minimal Residual Disease, Circulating Tumor Cell	Phase 2	Active, closed	Fundación para la Investigación del Hospital Clínico de Valencia	Spain
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC NCT04068610 · Metastatic Microsatellite-stable Colorectal Cancer	Phase 1/2	Active, closed	MedImmune LLC	USA, France, Spain, Canada, Australia
ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer. NCT05632939 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Cancer (GC)	Phase 1/2	Active, closed	AskGene Pharma, Inc	China
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers NCT04485013 · Cancer	Phase 1	Active, closed	Tizona Therapeutics, Inc	USA
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors NCT05848739 · Colon Cancer, Metastatic Colon Cancer	Phase 1	Active, closed	Sapience Therapeutics	USA, Israel

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Folfox

126 conditions

Colorectal Cancer11 Metastatic Colorectal Cancer7 Rectal Cancer7 Colon Cancer5 Solid Tumors4 Pancreatic Ductal Adenocarcinoma4 Colorectal Cancer Metastatic4CRC3Gastric Cancer3 Chemotherapy3 Advanced Colorectal Cancer2 Advanced Solid Tumors2

All 126 conditions

Condition (as registered)	Trials
Colorectal Cancer	11
Metastatic Colorectal Cancer	7
Rectal Cancer	7
Colon Cancer	5
Solid Tumors	4
Pancreatic Ductal Adenocarcinoma	4
Colorectal Cancer Metastatic	4
CRC	3
Gastric Cancer	3
Chemotherapy	3
Advanced Colorectal Cancer	2
Advanced Solid Tumors	2
Unresectable Metastatic Colorectal Cancer	2
Non-Small Cell Lung Cancer	2
Metastatic Colorectal Cancer (mCRC)	2
Colorectal Carcinoma	2
Metastatic Colorectal Cancer (CRC)	2
Intrahepatic Cholangiocarcinoma (Icc)	2
CRC (Colorectal Cancer)	2
Biliary Tract Cancer (BTC)	2
Solid Tumor, Adult	2
Gastric Adenocarcinoma	2
PD-1 Inhibitor	2
Biliary Tract Cancer	2
Locally Advanced Rectal Cancer	2
Gastroesophageal Junction Adenocarcinoma	2
ctDNA	2
Locally Advanced Rectal Cancer (LARC)	2
Untreated, Unresectable, or Metastatic Colorectal Cancer	1
Metastatic Solid Tumors	1
Colorectal Neoplasms	1
Gastrointestinal Neoplasms	1
Left-sided Colorectal Cancer	1
Metastatic Colon Cancer	1
KRAS/NRAS Mutation	1
PDAC	1
Ovarian Cancer	1
Endometrial Cancer	1
Cholangiocarcinoma	1
Ras-mutated Metastatic Colorectal Cancer	1
mCRC	1
MSS Metastatic Colorectal Cancer	1
Cancer	1
Unresectable/Metastatic Colorectal Cancer	1
Colorectal Cancer Liver Metastasis	1
Microsatellite Stable (MSS) Colorectal Cancer (CRC)	1
KRAS G12C Mutation	1
Non-small Cell Lung Cancer	1
Histiocytic Neoplasm	1
Histiocytosis	1
BRAF Gene Mutation	1
Neuroendocrine Carcinoma	1
Neuroendocrine Neoplasm	1
Metastatic Pancreatic Adenocarcinoma	1
Carcinoma, Neuroendocrine	1
Locally Advanced Cancer	1
Metastatic Cancer	1
Metastatic Colorectal Adenocarcinoma	1
Recurrent Rectal Cancer	1
Tumor, Colorectal	1
Organoids	1
Tumoroid	1
RAS/BRAF Wild-type Advanced Colorectal Cancer Patients	1
Progression-Free Survival	1
Locally Advanced / Metastatic Solid Tumors	1
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma	1
Colonic Neoplasms	1
Neoplasms, Colon	1
Gastric or Gastroesophageal Junction Adenocarcinoma	1
Metastatic Breast Cancer	1
Advanced Breast Cancer	1
HER2 Mutation-Related Tumors	1
Metastatic Microsatellite-stable Colorectal Cancer	1
Locally Advanced Colorectal Carcinoma	1
Hepatic Arterial Infusion Chemotherapy	1
Microsatellite Stable Colorectal Carcinoma	1
RAS Mutation	1
Cadonilimab	1
Gastric (Stomach) Cancer	1
Fruquintinib	1
Hepatocellular Carcinoma (HCC)	1
Second Line Treatment	1
Tyrosine Kinase Inhibitor	1
Metastatic Colorectal Cancer With Left-sided Primary Tumor	1
Immunotherapy	1
Gastric Cancer (Diagnosis)	1
Intrahepatic Cholangiocellular Carcinoma	1
Gastroesophageal Adenocarcinoma	1
Digestive Cancer	1
Metastatic Esophageal Adenocarcinoma	1
Advanced Esophageal Adenocarcinoma	1
Metastatic Gastric Adenocarcinoma	1
Advanced Gastric Adenocarcinoma	1
Esophagus Adenocarcinoma	1
Liver Metastasis Colon Cancer	1
Locally Advanced Colorectal Cancer	1
Locally Advanced Rectal Carcinoma	1
Gastric / Gastroesophageal Junction Adenocarcinoma	1
Advanced Gastric Cancer	1
SHR1701	1
HER2-Gastric/Gastroesophageal Junction Cancer	1
Urothelial Carcinoma	1
Rectal Neoplasms	1
Rectal Cancer, Adenocarcinoma	1
Peritoneal Metastasis of Gastric and Colorectal Cancer	1
LDRT	1
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	1
Radiotherapy	1
Gastric Cancer Stage	1
Gastroesophageal Cancer (GC)	1
Gastric Carcinoma	1
pMMR (Microsatellite Stable Rectal Cancer)	1
Rectal Cancer Patients	1
Advanced Solid Tumor	1
Local Advanced Rectal Cancer	1
PCSK9 Inhibitor	1
RCT	1
Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma	1
CLDN18.2-positive Advanced Solid Tumor	1
Colo-rectal Cancer	1
Colon Carcinoma	1
Locally-advanced Rectal Cancer	1
Colorectal Neoplasms Malignant	1
Minimal Residual Disease	1
Circulating Tumor Cell	1
Ampullary Adenocarcinoma	1

By country register

Register	Trials	Recruiting
Clinical trials in China	59	36
Clinical trials in USA	26	21
Clinical trials in France	25	16
Clinical trials in Spain	20	15
Clinical trials in Italy	15	12
Clinical trials in South Korea	13	11
Clinical trials in Australia	13	11
Clinical trials in Germany	12	8
Clinical trials in UK	10	9
Clinical trials in Canada	10	8
Clinical trials in Japan	10	10
Clinical trials in Belgium	9	8
Clinical trials in Poland	8	7
Clinical trials in Taiwan	8	7
Clinical trials in Netherlands	7	6
Clinical trials in Brazil	7	6
Clinical trials in Denmark	6	5
Clinical trials in Mexico	5	4
Clinical trials in Austria	4	3
Clinical trials in Czechia	4	3
Clinical trials in Portugal	4	3
Clinical trials in Turkey	4	4
Clinical trials in Sweden	4	3
Clinical trials in Norway	4	4
Clinical trials in India	3	3
Clinical trials in Switzerland	3	3
Clinical trials in Ireland	2	1
Clinical trials in Singapore	2	1
Clinical trials in Israel	2	1
Clinical trials in Egypt	1	0

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Folfox trials

How many clinical trials are testing Folfox?

108 current trials in our China, USA, France, Spain, Italy, South Korea, Australia, Germany, UK, Canada, Japan, Belgium, Poland, Taiwan, Netherlands, Brazil, Denmark, Mexico, Austria, Czechia, Portugal, Turkey, Sweden, Norway, India, Switzerland, Ireland, Singapore, Israel and Egypt registers name Folfox (also registered as Fluorouracil (5-FU)) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Folfox trials recruiting patients?

Yes. 67 of the 108 trials are recruiting: 36 with sites in China, 21 with sites in USA, 16 with sites in France, 15 with sites in Spain, 12 with sites in Italy, 11 with sites in South Korea, 11 with sites in Australia, 8 with sites in Germany, 9 with sites in UK, 8 with sites in Canada, 10 with sites in Japan, 8 with sites in Belgium, 7 with sites in Poland, 7 with sites in Taiwan, 6 with sites in Netherlands, 6 with sites in Brazil, 5 with sites in Denmark, 4 with sites in Mexico, 3 with sites in Austria, 3 with sites in Czechia, 3 with sites in Portugal, 4 with sites in Turkey, 3 with sites in Sweden, 4 with sites in Norway, 3 with sites in India, 3 with sites in Switzerland, 1 with sites in Ireland, 1 with sites in Singapore and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Folfox clinical trials?

Fudan University (8), Sun Yat-sen University (6), UNICANCER (5) and Incyte Corporation (3), among 80 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Folfox clinical trials in Ireland?

Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Folfox works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Folfox works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Folfox (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.